Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
LYON, France, May 2, 2018 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the first quarter ended March 31, 2018, after the close of the financial markets on Monday, May 14, 2018.
An accompanying conference call will be conducted by Philippe Chauveau, Chairman of the Board; Marc Oczachowski, Chief Executive Officer; and François Dietsch, Chief Financial Officer, to review the results. The call will be held at 8:30 AM ET, on Tuesday, May 15, 2018. Please refer to the information below for conference call dial-in information and webcast registration.
Conference Call & Webcast
Tuesday, May 15, 2018 @ 8:30am Eastern Time
Domestic: 866-548-4713
International 323-794-2093
Passcode: 9225280
Webcast: http://public.viavid.com/index.php?id=129164
Replays, Available through May 29, 2018:
Domestic: 844-512-2921
International: 412-317-6671
Replay PIN: 9225280
About EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® (currently pending FDA clearance) in 2013 as the answer to all requirements for ideal prostate tissue ablation as a complement to the existing FDA cleared Ablatherm® Robotic HIFU and Ablatherm® Fusion. As a pioneer and key player in the field of extracorporeal shock wave lithotripsy (ESWL), EDAP TMS exclusively utilizes the latest generation of shock wave source in its Sonolith® range of ESWL systems. For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.
CONTACTS:
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
[email protected]
Jeremy Feffer
LifeSci Advisors, LLC
212-915-2568
[email protected]
